Anticonvulsive properties of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor
Epilepsia2022Vol. 63(6), pp. 1580–1590
Citations Over TimeTop 10% of 2022 papers
Toshiya Nishi, Cameron S. Metcalf, Shinji Fujimoto, Shigeo Hasegawa, Maki Miyamoto, Eiji Sunahara, Sayuri Watanabe, Shinichi Kondo, H. Steve White
Abstract
The data collectively suggest that soticlestat can ameliorate seizure symptoms through a mechanism distinct from conventional antiseizure medications. With its novel mechanism of action, soticlestat could constitute a novel class of antiseizure medications for treatment of intractable epilepsy disorders such as developmental and epileptic encephalopathy.
Related Papers
- → Pentylenetetrazol (PTZ) Kindling Model of Epilepsy(2012)318 cited
- → MK-801 prevents chemical kindling induced by pentylenetetrazol in rats(1991)69 cited
- → Pentylenetetrazol kindling in mice(1989)44 cited
- → A study of pentylenetetrazol kindling in rats and mice(1988)23 cited
- [Development of pentylenetetrazol kindling model].(1993)